Articles On Kazia Therapeutics (ASX:KZA)

ShareCafeWhy Kazia Therapeutics is Australia’s biotech shining star Kazia Therapeutics share price has been driven by strong buying in their US-listed ADRs with the company’s market capitalisation moving from $75m to $200m since the Corpora...

Summary Kazia Therapeutics has announced that it will present the summary of paxalisib’s new Phase II study data at the SNO Annual Meeting to be held during 19-21 November. The new interim data of paxalisib in glioblastoma is consistent...

The paxalisib Phase II study remains ongoing, with final data expected in the first half of 2021.

During the September quarter the company’s Paxalisib drug was granted special designations by US FDA, Rare Pediatric Disease Designation in DIPG, Orphan Designation in glioma, and Fast Track Designation in glioblastoma.

The company’s investigational new drug paxalisib is being developed to treat glioblastoma (GBM), an aggressive type of brain cancer, and other cancers.

Kazia is laying the groundwork to develop its investigational new drug paxalisib for glioblastoma and other types of cancers.

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced it has executed a definitive agreement with the Global Coalition for Adaptive Research to commence its participation in the GBM AGILE pivot...

GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is an international platform study that has been established specifically to facilitate the approval of new medicines for glioblastoma.

Proceeds form the entitlement offer will position Kazia as a late-stage global oncology company with a highly-compelling asset and a well-funded path to market.

By Peter Switzer, Switzer Report Lots of smaller companies I like One thing I’ve personally learnt this year is the power of small cap companies to drive your portfolio’s value higher. This revelation makes me even more committed to the ide...

ShareCafeAntisense Eyes A ‘Golden Ticket’ In The US – And Early European Approval For Its Rare Childhood Disease Therapy Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its n...

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced the successful completion of the institutional component of its capital raise.

A number of companies got a nice share price boost after positive announcements this week Starpharma and Kazia Therapeutics launched ... Read More The post ScoPo’s Health Powerplays: Biotechs hitting it out of the park appeared first on Sto...

The funding will position Kazia as a late-stage global oncology company with a highly-compelling asset and a well-funded path to market.

The financing will position Kazia as a late-stage global oncology company with a highly-compelling asset and a well-funded path to market.

The Dana-Farber Cancer institute will initiate an open-label phase II clinical trial of paxalisib in primary central nervous system lymphoma, which is expected to recruit up to 25 patients, and take up to two years to complete.

Sydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund its participation in an international bran cancer study.

ShareCafeKazia Therapeutic’s New Collaboration Gives Their Cancer Drug New Potential For Treatment Of Lymphoma   Kazia Therapeutics (ASX: KZA) is an Australian oncology company developing high-impact drugs for cancer. paxalisib, which is b...

The institute will initiate an open-label phase II clinical trial of paxalisib in primary central nervous system lymphoma, which is expected to recruit up to 25 patients, and take up to two years to complete.

Kazia said the collaboration will investigate the use of its investigational new drug, paxalisib (formerly GDC-0084), in primary central nervous system lymphoma.

Edison Investment Research has reinitiated coverage on Kazia with a valuation of A$145 million or A$1.54 per share.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Earnings s...

The company’s paxalisib treatment for malignant glioma has been recently granted Orphan Drug Designation by the US FDA.

ShareCafeWith A ‘Ticket To Ride’, Kazia Wows Investors With Its Rare-Cancer Story   As the political schisms in the US widen there’s one element that does not discriminate between the major parties: the most common form of brain cancer. Kn...

This status for potential treatments for rare diseases provides a period of 7.5 years data exclusivity (for a paediatric disease), which allows developers to extend the effective life of a commercial product.

A quick wrap of the ASX’s key winners and losers on Thursday, August 20. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 553 stocks rose, 765 declined and...

Kazia Therapeutics Ltd (ASX: KZA) share price has skyrocketed 34% today after announcing the US Food and Drug Administration (FDA) had granted fast track designation (FTD) for Kazia’s drug, paxalisib. Paxalisib is used for the treatment of...

Just under two weeks ago, Kazia Therapeutics Ltd [ASX:KZA] was making headlines. The company had received ‘the nod’ from the US Food and Drug Administration (FDA) it sorely needed... The post Kazia Therapeutics Share Price Storms Higher on...

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has been granted Fast Track Designation by the US Food & Drug Administration for its lead drug paxalisib (formerly GDC-0084) for the treatment of glioblasto...

Cancer-fighting biotech Kazia Therapeutics (ASX:KZA) has received another approval from US health authorities, as it continues with phase II clinical trials for its brain cancer treatment. The company announced its paxalisib treatment has b...

Fast Track Designation (FTD) is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Kazia Therapeutics (ASX:KZA), an Australian oncology-focused biotechnology company, has announced that the US FDA has granted Fast Track Designation (FTD) to its paxalisib (formerly GDC-0084) for the treatment of glioblastoma.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Summary Kazia Therapeutics’ paxalisib awarded Rare Pediatric Disease Designation by the US FDA. With the RPDD grant, Kazia Therapeutics may now be eligible to receive a rare pediatric disease priority review voucher if paxalisib gets ap...

The share price of oncology-focused biotech firm, KAZIA Therapeutics Ltd [ASX:KZA], soared this morning on the receipt of FDA designation for its brain cancer treatment. At time of writing the KZA share price is up 26 cents or 46.43%, tradi...

A quick wrap of the ASX’s key winners and losers on Friday, August 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 679 stocks rose, 666 dec...

The Kazia Therapeutics Ltd (ASX: KZA) share price has today smashed its 52-week high on news that the United States Food and Drug Administration (FDA) has awarded a grant for Kazia’s flagship drug. The oncology-focused biotech company has...

The US FDA has awarded RPDD to paxalisib for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and highly aggressive childhood brain cancer.

The US FDA has awarded RPDD to paxalisib for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and highly aggressive childhood brain cancer.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Kazia Therapeutics (ASX: KZA) has been awarded Rare Pediatric Disease Designation (RPDD) for its lead drug paxalisib by the FDA for treating Diffuse Intrinsic Pontine Glioma (DIPG). RPDD status means Kazia is now eligible to receive a what’...

Bell Financial Group (ASX:BFG) is expecting to book a higher $23.5m first-half profit, but investors didn’t seem overly happy about it with shares dipping 5.2 per cent on Friday morning. The figure is 5 per cent up on the same period last y...

ShareCafeKazia Therapeutics – ShareCafe Hidden Gems Webinar Presentation   Kazia Therapeutics CEO Dr. James Garner presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Kazia is an innovative oncology-focused biotechnology compan...

ShareCafeHidden Gems Webinar Recap – SPT, KZA, MEM, ANP   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the most recent edition with presentations from Splitit Payments Ltd (ASX:SPT), Kaz...

The Cantrixil phase I study is now complete and analysis is underway, with final data expected in the second half of calendar 2020.

The biotech has delivered all milestones to date, with multiple data read-outs expected over 6-12 months.

ShareCafeUnderstanding Biotechs Starts With Understanding How Drugs Are Named? Drugs and biologics often end up with multiple names as they travel through the development and commercialisation. It can all get very confusing and even more so...